Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of MK-4464 alone and with pembrolizumab in advanced or metastatic solid tumors
NL-OMON53771Phase 1Recruiting
- Sponsor
- Merck & Co.
- Start
- Mar 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of MK-4464 and pembrolizumab in Nonhematologic neoplasms, colorectal cancer (CRC), gastric adenocarcinoma and 3 more (2 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicity, Adverse events and 1 more. Started Mar 2023; status: recruiting.
02
Drugs
MK-4464pembrolizumab
03
Conditions
Nonhematologic neoplasmscolorectal cancer (CRC)gastric adenocarcinomaesophageal cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NL-OMON53771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53771.